Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 16, 2023, by Vivos Therapeutics, Inc., a Delaware corporation. The filing serves to announce the Company's financial results for the second quarter ended June 30, 2023. The Company is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the main text. Investors must refer to the referenced press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, and unusual items are not detailed in the provided text. The filing states that the information in the press release shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability for those specific statements.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2023 revenue, net loss, and cash burn figures.
- Verify the Company's cash position and runway as disclosed in the full press release.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the referenced exhibit.
- Check for any new debt obligations or equity financing activities not detailed in this summary.